Development of mycobacterium tuberculosis whole cell screening hits as potential antituberculosis agents

Journal of Medicinal Chemistry

Volumn 56, Issue 20, 2013, Pages 7755-7760

  Cooper, Christopher B ^a  

^a Global Alliance for TB Drug Development (TB Alliance)   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINOTHIAZOLE 4 CARBOXYLATE DERIVATIVE; 6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; BEDAQUILINE; BTZ 043; DELAMANID; N (2 ADAMANTYL) N' GERANYLETHYLENEDIAMINE; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ARTICLE; CELL SCREENING; DRUG SCREENING; DRUG STRUCTURE; MYCOBACTERIUM TUBERCULOSIS; WHOLE CELL;

ANTITUBERCULAR AGENTS; CHEMISTRY, PHARMACEUTICAL; DRUG DESIGN; DRUG DISCOVERY; HUMANS; MOLECULAR STRUCTURE; MOLECULAR TARGETED THERAPY; MYCOBACTERIUM TUBERCULOSIS; PHENOTYPE; TUBERCULOSIS;

EID: 84886495995     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm400381v     Document Type: Article

References (37)

1. Global Tuberculosis Report-2012; World Health Organization: Geneva, 2012; pp 8-29, http://www.who.int/tb/publications/global-report/en/.
2. Global Tuberculosis Report-2012; World Health Organization: Geneva, 2012; pp 30-40, http://www.who.int/tb/publications/global-report/en/.
3. Global Tuberculosis Report-2012; World Health Organization: Geneva, 2012; pp 41-52, http://www.who.int/tb/publications/global-report/en/.
4. Dheda, K.; Migliori, G. B. The global rise of extensively drug-resistant tuberculosis: is the time to bring back sanatoria now overdue? Lancet 2012, 379, 773-775
5. Migliori, G. B.; Ortmann, J.; Girardi, E.; Besozzi, G.; Lange, C.; Cirillo, D. M.; Ferrarese, M.; De Iaco, G.; Gori, A.; Raviglione, M. C. Extensively Drug-resistant Tuberculosis, Italy and Germany Emerging Infect. Dis. 2007, 13 (5) 780-782
6. du Toit, L. C.; Pillay, V.; Danckwerts, M. P. Tuberculosis chemotherapy: current drug delivery approaches Respir. Res. 2006, 7 (118) 1-18
7. Panchagnula, R.; Agrawal, S.; Ashokraj, Y.; Varma, M.; Sateesh, K.; Bhardwaj, V.; Bedi, S.; Gulati, I.; Parmar, J.; Kaul, C. L.; Blomberg, B.; Fourie, B.; Roscigno, G.; Wire, R.; Laing, R.; Evans, P.; Moore, T. Fixed dose combinations for tuberculosis: lessons learned from clinical, formulation and regulatory perspective Methods Find. Exp. Clin. Pharmacol. 2004, 26 (9) 703
8. Quy, H. T.; Lönnroth, K.; Lan, N. T. N.; Buu, T. N. Int. J. Tuberculosis Lung Dis. 2003, 7 (12) 1139-1146
9. Migliori, G. B.; Centis, R.; D'Ambrosio, L.; Spanevello, A.; Borroni, E.; Cirillo, D. M.; Sotgiu, G. Totally Drug-Resistant and Extremely Drug-Resistant Tuberculosis: The Same Disease? Clin. Infect. Dis. 2012, 54 (9) 1379-1380
10. Koebler, J. Doctors Struggling to Fight 'Totally Drug-Resistant' Tuberculosis in South Africa. US News World Rep., 11 February 2013, (published online).
11. Cole, S. T.; Brosch, R.; Parkhill, J.; Garnier, T.; Churcher, C.; Harris, D.; Gordon, S. V.; Eiglmeier, K.; Gas, S.; Barry, C. E.; Tekaia, F.; Badcock, K.; Basham, D.; Brown, D.; Chillingworth, T.; Connor, R.; Davies, R.; Devlin, K.; Feltwell, T.; Gentles, S.; Hamlin, N.; Holroyd, S.; Hornsby, T.; Jagels, K.; Krogh, A.; McLean, J.; Moule, S.; Murphy, L.; Oliver, K.; Osborne, J.; Quail, M. A.; Rajandream, M. A.; Rogers, J.; Rutter, S.; Seeger, K.; Skelton, J.; Squares, R.; Squares, S.; Sulston, J. E.; Taylor, K.; Whitehead, S.; Barrell, B. G. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence Nature 1998, 393 (6685) 537-544
12. Rawls, K. A.; Lang, P. T.; Takeuchi, J.; Imamura, S.; Baguley, T. D.; Grundner, C.; Alber, T.; Ellman, J. A. Fragment-based discovery of selective inhibitors of the Mycobacterium tuberculosis protein tyrosine phosphatase PtpA Bioorg. Med. Chem. Lett. 2009, 19 (24) 6851-6854
13. Manger, M.; Scheck, M.; Prinz, H.; von Kries, J. P.; Langer, T.; Saxena, K.; Schwalbe, H.; Fürstner, A.; Rademann, J.; Waldmann, H. Discovery of Mycobacterium tuberculosis protein tyrosine phosphatase A (MptpA) inhibitors based on natural products and a fragment-based approach ChemBioChem 2005, 6, 1749-1753
14. Ellman, J. A.; Rawls, K. A.; Grundner, C. Design and Synthesis of Nonpeptidic, Small Molecule Inhibitors for the Mycobacterium tuberculosis Protein Tyrosine Phosphatase PtpB Org. Biomol. Chem. 2010, 8 (18) 4066-4070
15. Soellner, M. B.; Rawls, K. A.; Grundner, C.; Alber, T.; Ellman, J. A. Fragment-based substrate activity screening method for the identification of potent inhibitors of the Mycobacterium tuberculosis phosphatase PtpB J. Am. Chem. Soc. 2007, 129 (31) 9613-9615
16. Coxon, G. D.; Cooper, C. B.; Gillespie, S. H.; McHugh, T. D. Strategies and challenges involved in the discovery of new chemical entities during early-stage tuberculosis drug discovery J. Infect. Dis. 2012, 205 (Suppl 2) S258-S264
17. Payne, D. J.; Gwynn, M. N.; Holmes, D. J.; Pompliano, D. L. Drugs for bad bugs: confronting the challenges of antibacterial discovery Nature Rev. Drug Discovery 2007, 6 (1) 29-40
18. Ananthan, S.; Faaleolea, E. R.; Goldman, R. C.; Hobrath, J. V.; Kwong, C. D.; Laughon, B. E.; Maddry, J. A.; Mehta, A.; Rasmussen, L.; Reynolds, R. C.; Secrist, J. A.; Shindo, N.; Showe, D. N.; Sosa, M. I.; Suling, W. J.; White, E. L. High-throughput screening for inhibitors of Mycobacterium tuberculosis H37Rv Tuberculosis 2009, 89 (5) 334-353
19. Jones, D.; Metzger, H. J.; Schatz, A.; Waksman, S. A. Control Of Gram-Negative Bacteria In Experimental Animals By Streptomycin Science 1944, 100 (2588) 103-105
20. Andries, K.; Verhasselt, P.; Guillemont, J.; Göhlmann, H. W.; Neefs, J. M.; Winkler, H.; Van Gestel, J.; Timmerman, P.; Zhu, M.; Lee, E.; Williams, P.; de Chaffoy, D.; Huitric, E.; Hoffner, S.; Cambau, E.; Truffot-Pernot, C.; Lounis, N.; Jarlier, V. A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis Science 2005, 307 (5707) 223-227
21. Cohen, J. Approval of Novel TB Drug Celebrated-With Restraint. Sciencemag.org, 11 January 2013, 339 (published online)
22. Edney, A. J&J Sirturo Wins FDA Approval to Treat Drug-Resistant TB. Bloomberg.com, 31 December 2012, (published online).
23. Stover, C. K.; Warrener, P.; VanDevanter, D. R.; Sherman, D. R.; Arain, T. M.; Langhorne, M. H.; Anderson, S. W.; Towell, J. A.; Yuan, Y.; McMurray, D. N.; Kreiswirth, B. N.; Barry, C. E.; Baker, W. R. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis Nature 2000, 405 (6789) 962-966
24. Matsumoto, M.; Hashizume, H.; Tomishige, T.; Kawasaki, M.; Tsubouchi, H.; Sasaki, H.; Shimokawa, Y.; Komatsu, M. OPC-67683, a Nitro-dihydro- imidazooxazole Derivative with Promising Action against Tuberculosis in Vitro and In Mice PLoS Med. 2006, 3 (11) e466
25. Protopopova, M.; Hanrahan, C.; Nikonenko, B.; Samala, R.; Chen, P.; Gearhart, J.; Einck, L.; Nacy, C. A. Identification of a new antitubercular drug candidate, SQ109, from a combinatorial library of 1,2-ethylenediamines J. Antimicrob. Chemother. 2005, 56 (5) 968-974
26. Makarov, V.; Manina, G.; Mikusova, K.; Möllmann, U.; Ryabova, O.; Saint-Joanis, B.; Dhar, N.; Pasca, M. R.; Buroni, S.; Lucarelli, A. P.; Milano, A.; De Rossi, E.; Belanova, M.; Bobovska, A.; Dianiskova, P.; Kordulakova, J.; Sala, C.; Fullam, E.; Schneider, P.; McKinney, J. D.; Brodin, P.; Christophe, T.; Waddell, S.; Butcher, P.; Albrethsen, J.; Rosenkrands, I.; Brosch, R.; Nandi, V.; Bharath, S.; Gaonkar, S.; Shandil, R. K.; Balasubramanian, V.; Balganesh, T.; Tyagi, S.; Grosset, J.; Riccardi, G.; Cole, S. T. Benzothiazinones Kill Mycobacterium tuberculosis by Blocking Arabinan Synthesis Science 2009, 324 (5928) 801-804
27. v and the β-Ketoacyl-ACP Synthase mtFabH PLoS One 2009, 4 (5) e5617
28. Maddry, J. A.; Ananthan, S.; Goldman, R. C.; Hobrath, J. V.; Kwong, C. D.; Maddox, C.; Rasmussen, L.; Reynolds, R. C.; Secrist, J. A.; Sosa, M. I.; White, E. L.; Zhang, W. Antituberculosis Activity of the Molecular Libraries Screening Center Network Library Tuberculosis 2009, 89 (5) 354-363
29. Goldman, R. C.; Laughon, B. E. Discovery and Validation of New Antitubercular Compounds as Potential Drug Leads and Probes Tuberculosis 2009, 89 (5) 331-333
30. Falzari, K.; Zhu, Z.; Pan, D.; Liu, H.; Hongmanee, P.; Franzblau, S. G. In Vitro and in Vivo Activities of Macrolide Derivatives against Mycobacterium tuberculosis Antimicrob. Agents Chemother. 2005, 49 (4) 1447-1454
31. Tuberculosis Strategy Overview Bill & Melinda Gates Foundation: Seattle, WA, 2013; http://www.gatesfoundation.org/What-We-Do/Global-Health/ Tuberculosis.
32. Ballell, L.; Bates, R. H.; Young, R. J.; Alvarez-Gomez, D.; Alvarez-Ruiz, E.; Barroso, V.; Blanco, D.; Crespo, B.; Escribano, J.; González, R.; Lozano, S.; Huss, S.; Santos-Villarejo, A.; Martín-Plaza, J. J.; Mendoza, A.; Rebollo-Lopez, M. J.; Remuiñan-Blanco, M.; Lavandera, J. L.; Pérez-Herran, E.; Gamo-Benito, F. J.; García-Bustos, J. F.; Barros, D.; Castro, J. P.; Cammack, N. Fueling Open-Source Drug Discovery: 177 Small-Molecule Leads against Tuberculosis ChemMedChem 2013, 8, 313-321
33. Kajbaf, M.; Longhi, R.; Montanari, D.; Vinco, F.; Rigo, M.; Fontana, S.; Read, K. D. A Comparative Study of the CYP450 Inhibition Potential of Marketed Drugs Using Two Fluorescence Based Assay Platforms Routinely Used in the Pharmaceutical Industry Drug Metab. Lett. 2011, 5, 30-39
34. Sharma, U. Current possibilities and unresolved issues of drug target validation in Mycobacterium tuberculosis Expert Opin. Drug Discovery 2011, 6 (11) 1171-1186 and references cited therein.
35. James, J. N.; Hasan, Z.-u.; Ioerger, T. R.; Brown, A. C.; Personne, Y.; Carroll, P.; Ikeh, M.; Tilston-Lunel, N. L.; Palavecino, C.; Sacchettini, J. C.; Parish, T. Deletion of SenX3-RegX3, a key two-component regulatory system of Mycobacterium smegmatis, results in growth defects under phosphate-limiting conditions Microbiology 2012, 158 (11) 2724-2731
36. Agarwal, N.; Pareek, M.; Thakur, P.; Pathak, V. Functional characterization of EngA(MS), a P-loop GTPase of Mycobacterium smegmatis PLoS One 2012, 7 (4) e34571
37. Edwards, A., University of Toronto Structural Genomics Consortium (personal communications).